L01XX14 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 75 | クッシング病 | 1 |
75. クッシング病
臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004019-29-IT (EUCTR) | 15/07/2021 | 07/10/2020 | Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cushing's disease. | Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study. - CRACCA | Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient. MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA Other descriptive name: NON COMMERCIAL Trade Name: VESANOID Product Name: Tretinoina Product Code: [L01XX14] INN or Proposed INN: TRETINOINA Other descriptive name: NON COMMERCIAL | Dipartimento di Medicina-DIMED, università di Padova | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Italy |